Japan’s health ministry approved a slew of new medicines on September 25 including multiple “first of its kind” products, among them being GlaxoSmithKline’s respiratory syncytial virus (RSV) vaccine Arexvy as well as Eisai’s Alzheimer’s therapy Leqembi (lecanemab).Arexvy became the first…
HOME > REGULATORY
REGULATORY
- MHLW to Launch Pharma Affairs Study Group July 10, Drug Loss Up for Debate
July 4, 2023
- MHLW Panel OKs 282 More Health Damage Claims for COVID Vaccines
July 4, 2023
- Hiroyuki Uchiyama Tapped as Assistant Vice Minister for Pharma Promotion
July 3, 2023
- LDP Bigwigs Launch Study Group on Drug Discovery to Spur Innovation
July 3, 2023
- Average Annual Pay for PMDA Staffers at 7.71 Million Yen in FY2022
July 3, 2023
- MHLW Reports 3 New Cases of Inadvertent Use of Xocova in Pregnant Women
July 3, 2023
- Study Group of Lawmakers, Industry Urges Earlier Launch of Genome Analysis Project Organ
July 3, 2023
- MHLW Expert Panel’s Report Serves as Starting Line for Reform: Asst. Vice Minister
June 30, 2023
- Japan to Revise Generic Use Target to Value-Based Figure
June 30, 2023
- MHLW to Run Pilot Sale of Emergency Contraceptives without Prescription
June 29, 2023
- Japan Mulls Narrowing Down COVID-19 Jabs to Pfizer, but Some Lawmakers Are Skeptical
June 29, 2023
- PMDA Reviewing Anaphylaxis Risk for Xocova
June 29, 2023
- MHLW Shuffles Senior Bureaucrats, Jo Tapped as Chief of Pharma Bureau
June 28, 2023
- After Years of Debates, Wholesalers’ Negative Primary Margins Remain a Problem
June 28, 2023
- SCARDA, CEPI Ink Pact to Beef Up Collab for Vaccine Development
June 28, 2023
- Japan OKs Oncaspar, Lytgobi, Litfulo, Rinvoq/Keytruda Label Expansions and More
June 27, 2023
- Ryukaikon Calls for Correcting Excessive Yakkasa by Revising Distribution Guidelines
June 27, 2023
- Ryukaikon to Discuss Drug Categories to Be Separated from Bundled Trades
June 27, 2023
- Japan Reports World’s 1st Death from Oz Virus
June 26, 2023
- PMDA Reviewing Safety Risks for 10 Statin Drugs, Tirzepatide
June 26, 2023
ページ
A doctor member of the Central Social Insurance Medical Council (Chuikyo) on September 20 traded barbs with pharma leaders over…
The Ministry of Health, Labor and Welfare (MHLW) on September 19 proposed restructuring the Japanese generic industry by restricting the…
The Ministry of Health, Labor and Welfare (MHLW) plans to no longer require the implementation of additional PI clinical studies…
IntroductionCommercial transformation is a top priority for pharma leaders in Japan and rightfully so. In a market with low single…
In the run-up to FY2024 budget requests this summer, there were growing hopes in the pharmaceutical industry that the government's de-facto cap on increases in social security spending would finally be lifted. That did not happen, despite strong calls from…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…